LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $86.24, for a total transaction of $86,240.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Daniel Jeffrey Moore also recently made the following trade(s):
- On Thursday, March 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $88.31, for a total transaction of $88,310.00.
- On Thursday, February 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $83.32, for a total transaction of $83,320.00.
Shares of NASDAQ LIVN opened at $89.01 on Thursday. The company has a market capitalization of $4,308.02, a PE ratio of 25.27, a PEG ratio of 2.79 and a beta of 0.75. LivaNova PLC has a 52-week low of $50.10 and a 52-week high of $92.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.79 and a current ratio of 2.14.
LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.10. The firm had revenue of $278.40 million for the quarter, compared to the consensus estimate of $278.48 million. LivaNova had a negative net margin of 2.10% and a positive return on equity of 9.37%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.83 EPS. equities research analysts expect that LivaNova PLC will post 3.2 EPS for the current year.
A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Needham & Company LLC restated a “buy” rating and issued a $104.00 price target (up previously from $97.00) on shares of LivaNova in a research report on Wednesday, February 28th. Canaccord Genuity boosted their price target on shares of LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. ValuEngine upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of LivaNova from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $81.43.
Several large investors have recently added to or reduced their stakes in LIVN. Vaughan Nelson Investment Management L.P. bought a new stake in shares of LivaNova in the 4th quarter valued at $55,467,000. Hermes Investment Management Ltd. bought a new stake in shares of LivaNova in the 4th quarter valued at $39,663,000. Dimensional Fund Advisors LP increased its stake in shares of LivaNova by 42.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,317,901 shares of the company’s stock valued at $92,331,000 after acquiring an additional 395,672 shares in the last quarter. BlackRock Inc. increased its stake in shares of LivaNova by 3.2% in the 4th quarter. BlackRock Inc. now owns 4,796,615 shares of the company’s stock valued at $383,345,000 after acquiring an additional 149,678 shares in the last quarter. Finally, Guggenheim Capital LLC increased its stake in shares of LivaNova by 2,420.8% in the 4th quarter. Guggenheim Capital LLC now owns 146,079 shares of the company’s stock valued at $11,675,000 after acquiring an additional 140,284 shares in the last quarter. Institutional investors own 85.29% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/19/daniel-jeffrey-moore-sells-1000-shares-of-livanova-plc-livn-stock.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.